EXEL closed Thursday trading at $5.80, up 3.0% with IV30™ down 1.6%. The LIVEVOL® Pro Summary is included below.
Provided by Livevol
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184).
I found this stock using the real-time custom scan that searches for high vols relative to the short-term and long-term historical realized vol. But the truly unusual phenomenon I see is how the implied is rising as the realized volatility is dipping. We'll see that in a sec.
Custom Scan Details
Stock Price GTE $7 and LTE $70
IV30™ - HV20™ GTE 10
HV180™ - IV30™ LTE -8
Average Option Volume GTE 1,200
Industry isNot Bio-tech
Days After Earnings GTE 10 and LTE 60
The EXEL Charts Tab (two-years) is included below. The top portion is the stock price, the bottom is the vol (IV30™ - red vs HV20™ - blue vs HV180™ - pink).
Provided by Livevol
On the stock side we can see a very calm ride over the last-year, whereas two-years ago, this stock did whip and gap quite a bit. But what i really want to look at is the volatility.
Let's turn to the one-year IV30™ and HV20™ charts in isolation, below.
Provided by Livevol
So that red curve is the short-term implied volatility (the IV30™) and is just below an annual high. It has popped from 40% to now ~80%, so a 100% increase since late Sep. That in and f itself is interesting, especially considering that earnings are done, and not expected again until Feb.
But, there's more... Look at the blue curve, which is the historical realized volatility over the last 20 trading days (conveniently called HV20™). That peaked at around 45% as the IV30™ bottomed out, and now they have again diverged with HV20™ now at just 32.88% an IV30™ at 79.24%. In English, as the stock has been moving less and less, the option market reflects risk that it will move more and more. Hmm...
Finally, let's look to the Options Tab (below).
Provided by Livevol
Across the top we can see the monthly vols are priced to 79.42% for Dec and 72.87% for Feb. EXEL seems to be in play, right now...
This is trade analysis, not a recommendation.
Follow @OphirGottlieb
Tweet
Legal Stuff:
Options involve risk. Prior to buying or selling an option, an investor must receive a copy of Characteristics and Risks of Standardized Options. Investors need a broker to trade options, and must meet suitability requirements.
The information contained on this site is provided for general informational purposes, as a convenience to the readers. The materials are not a substitute for obtaining professional advice from a qualified person, firm or corporation. Consult the appropriate professional advisor for more complete and current information. I am not engaged in rendering any legal or professional services by placing these general informational materials on this website.
I specifically disclaims any liability, whether based in contract, tort, strict liability or otherwise, for any direct, indirect, incidental, consequential, or special damages arising out of or in any way connected with access to or use of the site, even if I have been advised of the possibility of such damages, including liability in connection with mistakes or omissions in, or delays in transmission of, information to or from the user, interruptions in telecommunications connections to the site or viruses.
I make no representations or warranties about the accuracy or completeness of the information contained on this website. Any links provided to other server sites are offered as a matter of convenience and in no way are meant to imply that I endorse, sponsor, promote or am affiliated with the owners of or participants in those sites, or endorse any information contained on those sites, unless expressly stated.
No comments:
Post a Comment